NCT06327724View on ClinicalTrials.gov

Belimumab in SLE Synovial Inflammation and Lymph Nodes

RecruitingOBSERVATIONAL

Enrollment

15

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

March 1, 2025

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Belimumab

Start of new treatment due to active disease

Trial Locations (1)

1100DD

RECRUITING

Amsterdam UMC; location Academic Medical Center, Amsterdam

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT06327724 - Belimumab in SLE Synovial Inflammation and Lymph Nodes | Biotech Hunter | Biotech Hunter